{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:01Z","timestamp":1791402301573,"version":"4.3.3"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Isavuconazole (ISA) is an attractive candidate for primary mold-active prophylaxis in high-risk patients with hematologic malignancies or hematopoietic cell transplant (HCT) recipients. However, data supporting the use of ISA for primary prophylaxis in these patients are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective review of breakthrough invasive fungal infections (bIFIs) among adult hematologic malignancy patients and HCT recipients who received \u22657 days of ISA primary prophylaxis between 1 September 2016 and 30 September 2018. The incidence of bIFIs in patients receiving ISA was compared to those receiving posaconazole (POS) and voriconazole (VOR) during the same time period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred forty-five patients received 197 courses of ISA prophylaxis. Twelve bIFIs (Aspergillus fumigatus [5], Aspergillus species [2], Mucorales [2], Fusarium species [2], and Candida glabrata [1]) occurred, representing 8.3% of patients and 6.1% of courses, after a median duration of 14 days of ISA prophylaxis. All bIFIs occurred during periods of neutropenia. Seven patients (58.3%) died within 42 days of onset of bIFI. In addition, bIFIs complicated 10.2% of ISA, 4.1% of POS, and 1.1% of VOR courses among patients with de novo or relapsed\/refractory acute myeloid leukemia during the study period, with invasive pulmonary aspergillosis (IPA) complicating 6.8% of ISA, 1.3% of POS, and zero VOR courses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although ISA has been approved for treatment of invasive Aspergillus and mucormycosis, we observed an increased rate of bIFI, notably IPA, using ISA for primary prophylaxis. These results support the need for further study to determine the role of ISA as primary prophylaxis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz282","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:31:17Z","timestamp":1554262277000},"page":"723-730","source":"Crossref","is-referenced-by-count":96,"title":["Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients"],"prefix":"10.1093","volume":"70","author":[{"given":"Lauren","family":"Fontana","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Perlin","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brie N","family":"Noble","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Oregon State University\/Oregon Health and Science University College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"James S","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Strasfeld","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Hakki","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"2021022211384208300_CIT0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.idc.2010.01.002","article-title":"Fungal infections in transplant and oncology patients","volume":"24","author":"Person","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"2021022211384208300_CIT0002","first-page":"JCO1800374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021022211384208300_CIT0003","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021022211384208300_CIT0004","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021022211384208300_CIT0005","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2021022211384208300_CIT0006","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"2021022211384208300_CIT0007","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021022211384208300_CIT0008","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021022211384208300_CIT0009","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2021022211384208300_CIT0010","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/DDDT.S145545","article-title":"Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy","volume":"12","author":"Jenks","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2021022211384208300_CIT0011","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021022211384208300_CIT0012","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13756-017-0282-0","article-title":"Seasonal clustering of sinopulmonary mucormycosis in patients with hematologic malignancies at a large comprehensive cancer center","volume":"6","author":"Sivagnanam","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"key":"2021022211384208300_CIT0013","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/cid\/civ507","article-title":"Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing","volume":"61","author":"White","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021022211384208300_CIT0014","first-page":"1610","article-title":"Breakthrough fungal infections in patients with leukemia receiving isavuconazole","volume":"67","author":"Rausch","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021022211384208300_CIT0015","volume-title":"M38-A2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008","edition":"2nd ed"},{"key":"2021022211384208300_CIT0016","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1128\/JCM.43.7.3324-3333.2005","article-title":"Multilocus DNA sequence comparisons rapidly identify pathogenic molds","volume":"43","author":"Rakeman","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2021022211384208300_CIT0017","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/jac\/dkt071","article-title":"Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases","volume":"68","author":"Zhao","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2021022211384208300_CIT0018","doi-asserted-by":"crossref","first-page":"e00893-18","DOI":"10.1128\/AAC.00893-18","article-title":"Clinical outcomes of oral suspension versus delayed-release tablet formulations of posaconazole for prophylaxis of invasive fungal infections","volume":"62","author":"Furuno","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021022211384208300_CIT0019","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021022211384208300_CIT0020","first-page":"1621","article-title":"Breakthrough invasive mold infections in the hematology patient: current concepts and future directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021022211384208300_CIT0021","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/cid\/ciy260","article-title":"Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: what is happening in the real-world setting?","volume":"67","author":"Fung","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021022211384208300_CIT0022","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cmi.2017.03.023","article-title":"Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates","volume":"23","author":"Astvad","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2021022211384208300_CIT0023","doi-asserted-by":"crossref","first-page":"e02240","DOI":"10.1128\/AAC.02240-17","article-title":"Detection of TR34\/L98H CYP51A mutation through passive surveillance for azole-resistant Aspergillus fumigatus in the United States from 2015 to 2017","volume":"62","author":"Berkow","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021022211384208300_CIT0024","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3201\/eid2501.171925","article-title":"Trends in azole resistance in Aspergillus fumigatus, the Netherlands, 1994\u20132016","volume":"25","author":"Buil","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2021022211384208300_CIT0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jac\/dkx354","article-title":"Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs","volume":"73","author":"Buil","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021022211384208300_CIT0026","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/cid\/cix130","article-title":"Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis","volume":"64","author":"Lamoth","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021022211384208300_CIT0027","doi-asserted-by":"crossref","first-page":"e01034","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021022211384208300_CIT0028","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure-response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021022211384208300_CIT0029","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/dkx423","article-title":"Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial","volume":"73","author":"Kontoyiannis","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz282\/28670536\/ciz282.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/5\/723\/36333232\/ciz282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/5\/723\/36333232\/ciz282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T11:39:42Z","timestamp":1613993982000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/5\/723\/5431181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,4,8]]},"published-print":{"date-parts":[[2020,2,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz282","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,1]]},"published":{"date-parts":[[2019,4,8]]}}}